NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO

Journal of Molecular and Cellular Cardiology

Volumn 36, Issue 3, 2004, Pages 411-421

  Yang, Xi Ming ^a   Krieg, Thomas ^a   Cui, Lin ^a   Downey, James M ^a   Cohen, Michael V ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Bradykinin; NECA; Nitric oxide; PI3 kinase; Reperfusion injury

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 8 (3 CHLOROSTYRYL)CAFFEINE; ACETYLCHOLINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); BRADYKININ; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; WORTMANNIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; REGULATORY MECHANISM; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); ANDROSTADIENES; ANIMALS; BRADYKININ; CAFFEINE; ENZYME INHIBITORS; FLAVONOIDS; INFARCTION; MITOGEN-ACTIVATED PROTEIN KINASES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; RECEPTORS, ADENOSINE A2; REPERFUSION; SIGNAL TRANSDUCTION; VASODILATOR AGENTS;

ORYCTOLAGUS CUNICULUS;

EID: 1542358806     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2003.12.008     Document Type: Article

References (47)

1. Olafsson B., Forman M.B., Puett D.W., Pou A., Cates C.U., Friesinger G.C., et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation. 76:1987;1135-1145.
2. Homeister J.W., Hoff P.T., Fletcher D.D., Lucchesi B.R. Combined adenosine and lidocaine administration limits myocardial reperfusion injury. Circulation. 82:1990;595-608.
3. Pitarys C.J. II, Virmani R., Vildibill H.D. Jr, Jackson E.K., Forman M.B. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation. 83:1991;237-247.
4. Norton E.D., Jackson E.K., Virmani R., Forman M.B. Effect of intravenous adenosine on myocardial reperfusion injury in a model with low myocardial collateral blood flow. Am Heart J. 122:1991;1283-1291.
5. Velasco C.E., Turner M., Cobb M.A., Virmani R., Forman M.B. Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: effect of intracoronary adenosine. Am Heart J. 122:1991;1561-1570.
6. 2-receptor agonists on myocardial reperfusion injury. Am Heart J. 123:1992;332-338.
7. Todd J., Zhao Z.-Q., Williams M.W., Sato H., Van Wylen D.G.L., Vinten-Johansen J. Intravascular adenosine at reperfusion reduces infarct size and neutrophil adherence. Ann Thorac Surg. 62:1996;1364-1372.
8. Zhao Z.-Q., Nakamura M., Wang N.-P., Wilcox J.N., Shearer S., Guyton R.A., et al. Administration of adenosine during reperfusion reduces injury of vascular endothelium and death of myocytes. Coronary Artery Dis. 10:1999;617-628.
9. Zhao Z.-Q., Budde J.M., Morris C., Wang N.-P., Velez D.A., Muraki S., et al. Adenosine attenuates reperfusion-induced apoptotic cell death by modulating expression of Bcl-2 and Bax proteins. J Mol Cell Cardiol. 33:2001;57-68.
10. Goto M., Miura T., Iliodoromitis E.K., O'Leary E.L., Ishimoto R., Yellon D.M., et al. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc Res. 25:1991;943-949.
11. 1-selective adenosine analogues protects the heart against infarction. Circulation. 85:1992;659-665.
12. Vander Heide R.S., Reimer K.A. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res. 31:1996;711-718.
13. 2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther. 286:1998;611-618.
14. Budde J.M., Velez D.A., Zhao Z.-Q., Clark K.L., Morris C.D., Muraki S., et al. Comparative study of AMP579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury during 24 h of reperfusion. Cardiovasc Res. 47:2000;294-305.
15. 1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drug Ther. 14:2000;607-614.
16. Xu Z., Cohen M.V., Downey J.M., Vanden Hoek T.L., Yao Z. Attenuation of oxidant stress during reoxygenation by AMP 579 in cardiomyocytes. Am J Physiol. 281:2001;H2585-H2589.
17. Baxter G.F., Ebrahim Z., Yellon D.M. Amp579, an A1/A2A agonist, limits infarct size at reperfusion via a P42/P44 MAPK-dependent pathway. Circulation. 102:2000;II-212. [Abstract].
18. Xu Z., Yang X.-M., Cohen M.V., Neumann T., Heusch G., Downey J.M. Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP 579 administered at reperfusion. J Mol Cell Cardiol. 32:2000;2339-2347.
19. 2 receptors. J Cardiovasc Pharmacol. 38:2001;474-481.
20. Xu Z., Jiao Z., Cohen M.V., Downey J.M. Protection from AMP 579 can be added to that from either cariporide or ischemic preconditioning in ischemic rabbit heart. J Cardiovasc Pharmacol. 40:2002;510-518.
21. Bell R.M., Yellon D.M. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol. 35:2003;185-193.
22. Qin Q., Downey J.M., Cohen M.V. Acetylcholine but not adenosine triggers preconditioning through PI3-kinase and a tyrosine kinase. Am J Physiol. 284:2003;H727-H734.
23. Krieg T., Qin Q., McIntosh E.C., Cohen M.V., Downey J.M. ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases. Am J Physiol. 283:2002;H2322-H2330.
24. Cohen M.V., Downey J.M. Ischemic preconditioning: description, mechanism, and significance. 4th ed Sperelakis N., Kurachi Y., Terzic A., Cohen M.V. Heart physiology and pathophysiology. 2001;867-885 Academic Press, San Diego.
25. Xu Z., Downey J.M., Cohen M.V. Timing and duration of administration are crucial for anti-infarct effect of AMP 579 infused at reperfusion in rabbit heart. Heart Dis. 5:2003;368-371.
26. Klotz K.-N. Adenosine receptors and their ligands. Naunyn-Schmiedebergs Arch Pharmacol. 362:2000;382-391.
27. ATP-channel activation. Am J Physiol. 273:1997;H1677-H1687.
28. 2a agonist CGS-21680 in infarcted and stunned porcine myocardium. Am J Physiol. 280:2001;H1660-H1666.
29. ATP channel opening and leads to cardioprotection. Am J Physiol. 286:2003;468-476.
30. Baxter G.F., Mocanu M.M., Brar B.K., Latchman D.S., Yellon D.M. Cardioprotective effects of transforming growth factor-β1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol. 38:2001;930-939.
31. Liao Z., Brar B.K., Cai Q., Stephanou A., O'Leary R.M., Pennica D., et al. Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion. Cardiovasc Res. 53:2002;902-910.
32. Jonassen A.K., Sack M.N., Mjøs O.D., Yellon D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res. 89:2001;1191-1198.
33. Qiu Y., Rizvi A., Tang X.-L., Manchikalapudi S., Takano H., Jadoon A.K., et al. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol. 273:1997;H2931-H2936.
34. Takano H., Tang X.-L., Qiu Y., Guo Y., French B.A., Bolli R. Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. Circ Res. 83:1998;73-84.
35. Bolli R., Dawn B., Tang X.-L., Qiu Y., Ping P., Xuan Y.-T., et al. The nitric oxide hypothesis of late preconditioning. Basic Res Cardiol. 93:1998;325-338.
36. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol. 33:2001;1897-1918.
37. Csonka C., Szilvássy Z., Fülöp F., Páli T., Blasig I.E., Tosaki A., et al. Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts. Circulation. 100:1999;2260-2266.
38. Lochner A., Marais E., Genade S., Moolman J.A. Nitric oxide: a trigger for classic preconditioning? Am J Physiol. 279:2000;H2752-H2765.
39. Qin Q., Yang X.-M., Cohen M.V., Critz S.D., Downey J.M. Bradykinin protects rabbit hearts by a NO- and cGMP-dependent pathway. J Mol Cell Cardiol. 35:2003;A29. [Abstract].
40. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 399:1999;601-605.
41. Gao F., Gao E., Yue T.-L., Ohlstein E.H., Lopez B.L., Christopher T.A., et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 105:2002;1497-1502.
42. Rakhit R.D., Mojet M.H., Marber M.S., Duchen M.R. Mitochondria as targets for nitric oxide-induced protection during simulated ischemia and reoxygenation in isolated neonatal cardiomyocytes. Circulation. 103:2001;2617-2623.
43. Rössig L., Fichtlscherer B., Breitschopf K., Haendeler J., Zeiher A.M., Mülsch A., et al. Nitric oxide inhibits caspase-3 by S-nitrosation in vivo. J Biol Chem. 274:1999;6823-6826.
44. Brookes P.S., Salinas E.P., Darley-Usmar K., Eiserich J.P., Freeman B.A., Darley-Usmar V.M., et al. Concentration-dependent effects of nitric oxide on mitochondrial permeability transition and cytochrome c release. J Biol Chem. 275:2000;20474-20479.
45. ATP channels. Circ Res. 89:2001;273-278.
46. Garrington T.P., Johnson G.L. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol. 11:1999;211-218.
47. Leinweber B.D., Leavis P.C., Grabarek Z., Wang C.-LA., Morgan K.G. Extracellular regulated kinase (ERK) interaction with actin and the calponin homology (CH) domain of actin-binding proteins. Biochem J. 344:1999;117-123.